{"id":77144,"date":"2026-11-17T19:38:49","date_gmt":"2026-11-17T19:38:49","guid":{"rendered":"https:\/\/www.stocktargetadvisor.com\/blog\/?p=77144"},"modified":"2026-11-17T19:38:49","modified_gmt":"2026-11-17T19:38:49","slug":"american-analyst-ratings-updates-november-13th-2026","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-13th-2026\/","title":{"rendered":"American Analyst Ratings Updates: November 13th, 2026"},"content":{"rendered":"<h1><a href=\"https:\/\/www.stocktargetadvisor.com\/blog\/?p=77144&amp;preview=true\">Analyst Ratings Updates (USA)<\/a><\/h1>\n<p><strong>Applied Aerospace &amp; Defense (AADX)<\/strong> \u2014 Guggenheim lowered its price target from $30.00 to $15.00 and maintained a Buy rating.<\/p>\n<p><strong>Applied Aerospace &amp; Defense (AADX)<\/strong> \u2014 Citigroup reiterated a Buy rating.<\/p>\n<p><strong>Aardvark Therapeutics (AARD)<\/strong> \u2014 Raymond James Financial reiterated a Market Perform rating.<\/p>\n<p><strong>Asbury Automotive Group (ABG)<\/strong> \u2014 Stephens downgraded its rating from Overweight to Equal Weight and has a price target of $200.00.<\/p>\n<p><strong>ACADIA Pharmaceuticals (ACAD)<\/strong> \u2014 Morgan Stanley lowered its price target from $28.00 to $24.00 and maintained an Equal Weight rating.<\/p>\n<p><strong>Array Digital Infrastructure (AD)<\/strong> \u2014 Citigroup lowered its price target from $45.00 to $43.00 and maintained a Buy rating.<\/p>\n<p><strong>Analog Devices (ADI)<\/strong> \u2014 Roth Capital initiated coverage with a Buy rating and set a price target of $505.00.<\/p>\n<p><strong>Autodesk (ADSK)<\/strong> \u2014 Loop Capital upgraded its rating from Hold to Buy and has a price target of $310.00.<\/p>\n<p><strong>Alliance Entertainment (AENT)<\/strong> \u2014 Noble Financial initiated coverage with a Strong Buy rating.<\/p>\n<p><strong>Agilon Health (AGL)<\/strong> \u2014 Zacks Research upgraded its rating from Hold to Strong Buy.<\/p>\n<p><strong>Agilon Health (AGL)<\/strong> \u2014 Wells Fargo raised its price target from $146.00 to $170.00 and maintained an Overweight rating.<\/p>\n<p><strong>Albany International (AIN)<\/strong> \u2014 Truist Financial raised its price target from $61.00 to $71.00 and maintained a Hold rating.<\/p>\n<p><strong>Arthur J. Gallagher &amp; Co. (AJG)<\/strong> \u2014 Mizuho raised its price target from $302.00 to $307.00 and maintained an Outperform rating.<\/p>\n<p><strong>Alector (ALEC)<\/strong> \u2014 Wells Fargo initiated coverage with an Overweight rating and set a price target of $7.00.<\/p>\n<p><strong>Allegro MicroSystems (ALGM)<\/strong> \u2014 Roth Capital initiated coverage with a Buy rating and set a price target of $40.00.<\/p>\n<p><strong>Align Technology (ALGN)<\/strong> \u2014 Zacks Research upgraded its rating from Strong Sell to Hold.<\/p>\n<p><strong>Alkami Technology (ALKT)<\/strong> \u2014 Stephens initiated coverage with an Equal Weight rating and set a price target of $15.00.<\/p>\n<p><strong>Almonty Industries (ALM)<\/strong> \u2014 Stifel lowered its price target from $21.00 to $18.00 and maintained a Buy rating.<\/p>\n<p><strong>Alumis (ALMS)<\/strong> \u2014 HC Wainwright lowered its price target from $15.00 to $9.00 and maintained a Buy rating.<\/p>\n<p><strong>Alumis (ALMS)<\/strong> \u2014 Wells Fargo lowered its price target from $25.00 to $18.00 and maintained an Overweight rating.<\/p>\n<p><strong>Altimmune (ALT)<\/strong> \u2014 Citigroup reiterated a Market Outperform rating.<\/p>\n<p><strong>Altimmune (ALT)<\/strong> \u2014 B. Riley Financial reiterated a Buy rating.<\/p>\n<p><strong>Alta Equipment Group (ALTG)<\/strong> \u2014 DA Davidson lowered its price target from $8.00 to $6.00 and maintained a Neutral rating.<\/p>\n<p><strong>Applied Materials (AMAT)<\/strong> \u2014 Jefferies Financial Group lowered its price target from $770.00 to $580.00 and maintained a Buy rating.<\/p>\n<p><strong>Applied Materials (AMAT)<\/strong> \u2014 Needham &amp; Company LLC lowered its price target from $580.00 to $470.00 and maintained a Buy rating.<\/p>\n<p><strong>Applied Materials (AMAT)<\/strong> \u2014 Bank of America lowered its price target from $650.00 to $520.00 and maintained a Buy rating.<\/p>\n<p><strong>Applied Materials (AMAT)<\/strong> \u2014 Stifel lowered its price target from $650.00 to $600.00 and maintained a Buy rating.<\/p>\n<p><strong>Applied Materials (AMAT)<\/strong> \u2014 Sanford C. Bernstein lowered its price target from $700.00 to $600.00 and maintained an Outperform rating.<\/p>\n<p><strong>Applied Materials (AMAT)<\/strong> \u2014 Summit Insights downgraded its rating from Buy to Hold.<\/p>\n<p><strong>Applied Materials (AMAT)<\/strong> \u2014 TD Securities lowered its price target from $700.00 to $500.00 and maintained a Buy rating.<\/p>\n<p><strong>Applied Materials (AMAT)<\/strong> \u2014 RBC reiterated an Outperform rating with a price target of $600.00.<\/p>\n<p><strong>Applied Materials (AMAT)<\/strong> \u2014 Wells Fargo lowered its price target from $610.00 to $500.00 and maintained an Overweight rating.<\/p>\n<p><strong>Applied Materials (AMAT)<\/strong> \u2014 KeyCorp reiterated an Overweight rating.<\/p>\n<p><strong>Applied Materials (AMAT)<\/strong> \u2014 UBS Group lowered its price target from $695.00 to $640.00 and maintained a Buy rating.<\/p>\n<p><strong>Applied Materials (AMAT)<\/strong> \u2014 Mizuho lowered its price target from $590.00 to $510.00 and maintained an Outperform rating.<\/p>\n<p><strong>Applied Materials (AMAT)<\/strong> \u2014 JPMorgan lowered its price target from $660.00 to $500.00 and maintained an Overweight rating.<\/p>\n<p><strong>AMETEK (AME)<\/strong> \u2014 Truist Financial reiterated a Buy rating with a price target of $316.00 ? $329.00.<\/p>\n<p><strong>Affiliated Managers Group (AMG)<\/strong> \u2014 Zacks Research upgraded its rating from Hold to Strong Buy.<\/p>\n<p><strong>Andersen Group (ANDG)<\/strong> \u2014 Robert W. Baird raised its price target from $64.00 to $71.00 and maintained an Outperform rating.<\/p>\n<p><strong>Andersen Group (ANDG)<\/strong> \u2014 Wells Fargo raised its price target from $49.00 to $61.00 and maintained an Equal Weight rating.<\/p>\n<p><strong>AON (AON)<\/strong> \u2014 Mizuho raised its price target from $363.00 to $373.00 and maintained an Outperform rating.<\/p>\n<p><strong>AON (AON)<\/strong> \u2014 Keefe, Bruyette &amp; Woods raised its price target from $342.00 to $376.00 and maintained an Outperform rating.<\/p>\n<p><strong>APA (APA)<\/strong> \u2014 Barclays raised its price target from $44.00 to $48.00 and maintained an Equal Weight rating.<\/p>\n<p><strong>Apollo Global Management (APO)<\/strong> \u2014 Piper Sandler downgraded its rating from Overweight to Cautious.<\/p>\n<p><strong>Apollo Global Management (APO)<\/strong> \u2014 UBS Group reiterated a Buy rating with a price target of $160.00.<\/p>\n<p><strong>Aptiv (APTV)<\/strong> \u2014 Daiwa Securities Group downgraded its rating from Outperform to Hold and has a price target of $41.00.<\/p>\n<p><strong>Ardent Health (ARDT)<\/strong> \u2014 Bank of America raised its price target from $12.00 to $14.00 and maintained an Underperform rating.<\/p>\n<p><strong>Alexandria Real Estate Equities (ARE)<\/strong> \u2014 Bank of America downgraded its rating from Neutral to Underperform and revised its price target from $55.00 to $45.00.<\/p>\n<p><strong>Alexandria Real Estate Equities (ARE)<\/strong> \u2014 Jefferies Financial Group downgraded its rating from Hold to Moderate Sell.<\/p>\n<p><strong>argenex (ARGX)<\/strong> \u2014 Morgan Stanley lowered its price target from $1,190.00 to $1,130.00 and maintained an Overweight rating.<\/p>\n<p><strong>Arrowhead Pharmaceuticals (ARWR)<\/strong> \u2014 RBC reiterated an Outperform rating with a price target of $100.00.<\/p>\n<p><strong>Arrowhead Pharmaceuticals (ARWR)<\/strong> \u2014 Stifel lowered its price target from $104.00 to $96.00 and maintained a Buy rating.<\/p>\n<p><strong>Ascendis Pharma A\/S (ASND)<\/strong> \u2014 HC Wainwright lowered its price target from $344.00 to $335.00 and maintained a Buy rating.<\/p>\n<p><strong>Ascendis Pharma A\/S (ASND)<\/strong> \u2014 Canaccord Genuity Group raised its price target from $268.00 to $274.00 and maintained a Hold rating.<\/p>\n<p><strong>Ascendis Pharma A\/S (ASND)<\/strong> \u2014 Cantor Fitzgerald raised its price target from $300.00 to $315.00 and maintained an Overweight rating.<\/p>\n<p><strong>Ascendis Pharma A\/S (ASND)<\/strong> \u2014 RBC reiterated an Outperform rating with a price target of $290.00.<\/p>\n<p><strong>Ascendis Pharma A\/S (ASND)<\/strong> \u2014 TD Securities raised its price target from $341.00 to $352.00 and maintained a Buy rating.<\/p>\n<p><strong>Ascendis Pharma A\/S (ASND)<\/strong> \u2014 UBS Group raised its price target from $269.00 to $315.00 and maintained a Buy rating.<\/p>\n<p><strong>Ascendis Pharma A\/S (ASND)<\/strong> \u2014 RBC set a price target of $352.00, with no accompanying rating specified.<\/p>\n<p><strong>Ascendis Pharma A\/S (ASND)<\/strong> \u2014 Raymond James Financial reiterated an Outperform rating.<\/p>\n<p><strong>Ascendis Pharma A\/S (ASND)<\/strong> \u2014 KeyCorp set a price target of $330.00, with no accompanying rating specified.<\/p>\n<p><strong>Ascendis Pharma A\/S (ASND)<\/strong> \u2014 Wells Fargo raised its price target from $326.00 to $330.00 and maintained an Overweight rating.<\/p>\n<p><strong>Alphatec (ATEC)<\/strong> \u2014 HC Wainwright lowered its price target from $24.00 to $20.00 and maintained a Buy rating.<\/p>\n<p><strong>ATI (ATI)<\/strong> \u2014 Citigroup raised its price target from $229.00 to $240.00 and maintained a Buy rating.<\/p>\n<p><strong>ATI (ATI)<\/strong> \u2014 BTIG Research raised its price target from $250.00 to $260.00 and maintained a Buy rating.<\/p>\n<p><strong>Aveanna Healthcare (AVAH)<\/strong> \u2014 RBC reiterated an Outperform rating.<\/p>\n<p><strong>Broadcom (AVGO)<\/strong> \u2014 Rothschild &amp; Co Redburn downgraded its rating from Buy to Neutral and revised its price target from $595.00 to $398.00.<\/p>\n<p><strong>Anteris Technologies Global (AVR)<\/strong> \u2014 Barclays lowered its price target from $10.00 to $9.00 and maintained an Equal Weight rating.<\/p>\n<p><strong>Avnet (AVT)<\/strong> \u2014 Bank of America lowered its price target from $115.00 to $110.00 and maintained a Neutral rating.<\/p>\n<p><strong>Axsome Therapeutics (AXSM)<\/strong> \u2014 Morgan Stanley lowered its price target from $249.00 to $223.00 and maintained an Equal Weight rating.<\/p>\n<p><strong>Brookfield Asset Management (BAM)<\/strong> \u2014 Wells Fargo raised its price target from $51.00 to $57.00 and maintained an Overweight rating.<\/p>\n<p><strong>BridgeBio Pharma (BBIO)<\/strong> \u2014 Morgan Stanley raised its price target from $88.00 to $91.00 and maintained an Overweight rating.<\/p>\n<p><strong>Bath &amp; Body Works (BBWI)<\/strong> \u2014 UBS Group raised its price target from $17.00 to $22.00 and maintained a Neutral rating.<\/p>\n<p><strong>Better Home &amp; Finance (BETR)<\/strong> \u2014 Cantor Fitzgerald changed its rating from Hold to Strong Sell.<\/p>\n<p><strong>Bilibili (BILI)<\/strong> \u2014 CLSA initiated coverage with a Strong Buy rating.<\/p>\n<p><strong>BJ&#8217;s Wholesale Club (BJ)<\/strong> \u2014 JPMorgan raised its price target from $100.00 to $113.00 and maintained a Neutral rating.<\/p>\n<p><strong>BJ&#8217;s Wholesale Club (BJ)<\/strong> \u2014 Wells Fargo raised its price target from $110.00 to $120.00 and maintained an Overweight rating.<\/p>\n<p><strong>BKV (BKV)<\/strong> \u2014 Barclays lowered its price target from $36.00 to $33.00 and maintained an Overweight rating.<\/p>\n<p><strong>Belite Bio (BLTE)<\/strong> \u2014 Leerink Partners raised its price target from $185.00 to $215.00 and maintained an Outperform rating.<\/p>\n<p><strong>BitMine Immersion Technologies (BMNR)<\/strong> \u2014 B. Riley Financial lowered its price target from $34.00 to $27.00 and maintained a Buy rating.<\/p>\n<p><strong>BioMarin Pharmaceutical (BMRN)<\/strong> \u2014 Morgan Stanley lowered its price target from $119.00 to $103.00 and maintained an Overweight rating.<\/p>\n<p><strong>Brookfield (BN)<\/strong> \u2014 RBC lowered its price target from $61.00 to $59.00 and maintained an Outperform rating.<\/p>\n<p><strong>Broadstone Net Lease (BNL)<\/strong> \u2014 Truist Financial raised its price target from $21.00 to $22.00 and maintained a Buy rating.<\/p>\n<p><strong>Popular (BPOP)<\/strong> \u2014 Hovde Group initiated coverage with a Hold rating and set a price target of $171.00.<\/p>\n<p><strong>Brown &amp; Brown (BRO)<\/strong> \u2014 Mizuho raised its price target from $81.00 to $84.00 and maintained an Outperform rating.<\/p>\n<p><strong>Boost Run (BRUN)<\/strong> \u2014 DA Davidson has a price target of $10.00 and maintained a Buy rating.<\/p>\n<p><strong>BSR Real Estate Investment Trust (BSRT)<\/strong> \u2014 RBC lowered its price target from $12.50 to $11.00 and maintained a Sector Perform rating.<\/p>\n<p><strong>BSR Real Estate Investment Trust (BSRT)<\/strong> \u2014 Desjardins lowered its price target from $12.50 to $11.50 and maintained a Buy rating.<\/p>\n<p><strong>Bit Digital (BTBT)<\/strong> \u2014 Zacks Research upgraded its rating from Hold to Strong Buy.<\/p>\n<p><strong>Peabody Energy (BTU)<\/strong> \u2014 UBS Group initiated coverage with a Strong Buy rating.<\/p>\n<p><strong>Burlington Stores (BURL)<\/strong> \u2014 Wells Fargo lowered its price target from $370.00 to $330.00 and maintained an Overweight rating.<\/p>\n<p><strong>Burlington Stores (BURL)<\/strong> \u2014 Gordon Haskett downgraded its rating from Hold to Reduce and has a price target of $240.00.<\/p>\n<p><strong>Broadwind Energy (BWEN)<\/strong> \u2014 Roth Capital lowered its price target from $6.50 to $5.00 and maintained a Buy rating.<\/p>\n<p><strong>BXP (BXP)<\/strong> \u2014 UBS Group lowered its price target from $70.00 to $66.00 and maintained a Neutral rating.<\/p>\n<p><strong>KANZHUN (BZ)<\/strong> \u2014 Barclays lowered its price target from $20.00 to $17.00 and maintained an Overweight rating.<\/p>\n<p><strong>KANZHUN (BZ)<\/strong> \u2014 86Research upgraded its rating from Hold to Buy and has a price target of $17.00.<\/p>\n<p><strong>Candel Therapeutics (CADL)<\/strong> \u2014 HC Wainwright lowered its price target from $23.00 to $18.00 and maintained a Buy rating.<\/p>\n<p><strong>Candel Therapeutics (CADL)<\/strong> \u2014 Stifel lowered its price target from $22.00 to $19.00 and maintained a Buy rating.<\/p>\n<p><strong>Candel Therapeutics (CADL)<\/strong> \u2014 Canaccord Genuity Group lowered its price target from $25.00 to $13.00 and maintained a Buy rating.<\/p>\n<p><strong>CAE (CAE)<\/strong> \u2014 Zacks Research upgraded its rating from Hold to Strong Buy.<\/p>\n<p><strong>Capricor Therapeutics (CAPR)<\/strong> \u2014 Roth Capital reiterated a Neutral rating with a price target of $7.00 ? $10.50.<\/p>\n<p><strong>Crescent Biopharma (CBIO)<\/strong> \u2014 HC Wainwright raised its price target from $36.00 to $40.00 and maintained a Buy rating.<\/p>\n<p><strong>Crescent Biopharma (CBIO)<\/strong> \u2014 Piper Sandler lowered its price target from $35.00 to $32.00 and maintained an Overweight rating.<\/p>\n<p><strong>Cerebras Systems (CBRS)<\/strong> \u2014 UBS Group lowered its price target from $250.00 to $155.00 and maintained a Buy rating.<\/p>\n<p><strong>Cerebras Systems (CBRS)<\/strong> \u2014 Needham &amp; Company LLC lowered its price target from $300.00 to $200.00 and maintained a Buy rating.<\/p>\n<p><strong>Cerebras Systems (CBRS)<\/strong> \u2014 Mizuho lowered its price target from $300.00 to $240.00 and maintained an Outperform rating.<\/p>\n<p><strong>Cerebras Systems (CBRS)<\/strong> \u2014 Wedbush set a price target of $205.00, with no accompanying rating specified.<\/p>\n<p><strong>Cardinal Infrastructure Group (CDNL)<\/strong> \u2014 Truist Financial lowered its price target from $30.00 to $10.00 and maintained a Buy rating.<\/p>\n<p><strong>Codere Online Luxembourg (CDRO)<\/strong> \u2014 Noble Financial initiated coverage with a Strong Buy rating.<\/p>\n<p><strong>Central Puerto (CEPU)<\/strong> \u2014 Zacks Research upgraded its rating from Hold to Strong Buy.<\/p>\n<p><strong>CF Industries (CF)<\/strong> \u2014 Sanford C. Bernstein reiterated an Outperform rating.<\/p>\n<p><strong>Cigna Group (CI)<\/strong> \u2014 Wells Fargo raised its price target from $307.00 to $325.00 and maintained an Equal Weight rating.<\/p>\n<p><strong>Chimera Investment (CIM)<\/strong> \u2014 RBC lowered its price target from $13.00 to $7.00 and maintained a Sector Perform rating.<\/p>\n<p><strong>Cellebrite DI (CLBT)<\/strong> \u2014 JPMorgan lowered its price target from $16.00 to $15.00 and maintained an Overweight rating.<\/p>\n<p><strong>Commercial Metals (CMC)<\/strong> \u2014 Barclays raised its price target from $72.00 to $77.00 and maintained an Equal Weight rating.<\/p>\n<p><strong>CNX Resources (CNX)<\/strong> \u2014 Barclays raised its price target from $35.00 to $36.00 and maintained an Underweight rating.<\/p>\n<p><strong>Americold Realty Trust (COLD)<\/strong> \u2014 Piper Sandler upgraded its rating from Neutral to Overweight and revised its price target from $15.00 to $19.00.<\/p>\n<p><strong>Concentra Group Holdings Parent (CON)<\/strong> \u2014 Wells Fargo raised its price target from $40.00 to $48.00 and maintained an Overweight rating.<\/p>\n<p><strong>ConocoPhillips (COP)<\/strong> \u2014 Barclays raised its price target from $150.00 to $165.00 and maintained an Overweight rating.<\/p>\n<p><strong>California Resources (CRC)<\/strong> \u2014 Barclays lowered its price target from $74.00 to $68.00 and maintained an Overweight rating.<\/p>\n<p><strong>CorMedix (CRMD)<\/strong> \u2014 Oppenheimer reiterated an Outperform rating with a price target of $15.00 ? $13.00.<\/p>\n<p><strong>Cisco Systems (CSCO)<\/strong> \u2014 Citigroup lowered its price target from $139.00 to $120.00 and maintained a Buy rating.<\/p>\n<p><strong>Cisco Systems (CSCO)<\/strong> \u2014 Barclays lowered its price target from $123.00 to $109.00 and maintained an Equal Weight rating.<\/p>\n<p><strong>Cisco Systems (CSCO)<\/strong> \u2014 Truist Financial lowered its price target from $140.00 to $127.00 and maintained a Buy rating.<\/p>\n<p><strong>Cisco Systems (CSCO)<\/strong> \u2014 Wells Fargo lowered its price target from $150.00 to $130.00 and maintained an Overweight rating.<\/p>\n<p><strong>Cisco Systems (CSCO)<\/strong> \u2014 Piper Sandler reiterated a Neutral rating with a price target of $125.00 ? $112.00.<\/p>\n<p><strong>Cisco Systems (CSCO)<\/strong> \u2014 Rosenblatt Securities lowered its price target from $165.00 to $140.00 and maintained a Buy rating.<\/p>\n<p><strong>Canadian Solar (CSIQ)<\/strong> \u2014 Zacks Research upgraded its rating from Strong Sell to Hold.<\/p>\n<p><strong>Cognizant Technology Solutions (CTSH)<\/strong> \u2014 Deutsche Bank downgraded its rating from Buy to Hold and revised its price target from $75.00 to $66.00.<\/p>\n<p><strong>Corteva (CTVA)<\/strong> \u2014 RBC lowered its price target from $17.00 to $11.00 and maintained an Outperform rating.<\/p>\n<p><strong>Corteva (CTVA)<\/strong> \u2014 UBS Group lowered its price target from $15.00 to $10.00 and maintained a Neutral rating.<\/p>\n<p><strong>Corteva (CTVA)<\/strong> \u2014 Oppenheimer downgraded its rating from Outperform to Market Perform.<\/p>\n<p><strong>Corteva (CTVA)<\/strong> \u2014 Citigroup lowered its price target from $13.65 to $10.30 and maintained a Neutral rating.<\/p>\n<p><strong>Corteva (CTVA)<\/strong> \u2014 JPMorgan lowered its price target from $19.00 to $16.00 and maintained an Overweight rating.<\/p>\n<p><strong>CVRx (CVRX)<\/strong> \u2014 Cantor Fitzgerald has a price target of $2.00 and maintained an Overweight rating.<\/p>\n<p><strong>CVS Health (CVS)<\/strong> \u2014 Sanford C. Bernstein reiterated an Outperform rating.<\/p>\n<p><strong>CVS Health (CVS)<\/strong> \u2014 Piper Sandler set a price target of $106.00, with no accompanying rating specified.<\/p>\n<p><strong>Chevron (CVX)<\/strong> \u2014 Barclays raised its price target from $244.00 to $248.00 and maintained an Equal Weight rating.<\/p>\n<p><strong>Clearway Energy (CWEN)<\/strong> \u2014 Truist Financial raised its price target from $40.00 to $42.00 and maintained a Buy rating.<\/p>\n<p><strong>DoorDash (DASH)<\/strong> \u2014 Rosenblatt Securities lowered its price target from $225.00 to $210.00 and maintained a Buy rating.<\/p>\n<p><strong>Dave (DAVE)<\/strong> \u2014 Freedom Capital upgraded its rating from Hold to Strong Buy.<\/p>\n<p><strong>Dave (DAVE)<\/strong> \u2014 Freedom Broker upgraded its rating from Hold to Buy and has a price target of $350.00.<\/p>\n<p><strong>Diversified Energy (DEC)<\/strong> \u2014 Zacks Research downgraded its rating from Strong Buy to Hold.<\/p>\n<p><strong>Journey Medical (DERM)<\/strong> \u2014 B. Riley Financial reiterated a Buy rating with a price target of $15.00 ? $13.00.<\/p>\n<p><strong>Dream Finders Homes (DFH)<\/strong> \u2014 Zelman &amp; Associates downgraded its rating from Outperform to Neutral.<\/p>\n<p><strong>Delek US (DK)<\/strong> \u2014 Mizuho lowered its price target from $83.00 to $80.00 and maintained a Neutral rating.<\/p>\n<p><strong>DICK&#8217;S Sporting Goods (DKS)<\/strong> \u2014 Wells Fargo raised its price target from $185.00 to $195.00 and maintained an Overweight rating.<\/p>\n<p><strong>Dolby Laboratories (DLB)<\/strong> \u2014 Zacks Research upgraded its rating from Strong Sell to Hold.<\/p>\n<p><strong>Digimarc (DMRC)<\/strong> \u2014 Needham &amp; Company LLC reiterated a Buy rating.<\/p>\n<p><strong>Denali Therapeutics (DNLI)<\/strong> \u2014 Wells Fargo initiated coverage with an Overweight rating and set a price target of $35.00.<\/p>\n<p><strong>Denali Therapeutics (DNLI)<\/strong> \u2014 Morgan Stanley lowered its price target from $42.00 to $37.00 and maintained an Overweight rating.<\/p>\n<p><strong>Domino&#8217;s Pizza (DPZ)<\/strong> \u2014 Robert W. Baird upgraded its rating from Neutral to Outperform and revised its price target from $320.00 to $400.00.<\/p>\n<p><strong>Domino&#8217;s Pizza (DPZ)<\/strong> \u2014 BMO Capital Markets reiterated an Outperform rating.<\/p>\n<p><strong>DarioHealth (DRIO)<\/strong> \u2014 Stifel has a price target of $5.00 and maintained a Buy rating.<\/p>\n<p><strong>DT Midstream (DTM)<\/strong> \u2014 The Goldman Sachs Group upgraded its rating from Sell to Neutral and revised its price target from $121.00 to $127.00.<\/p>\n<p><strong>Devon Energy (DVN)<\/strong> \u2014 Barclays raised its price target from $57.00 to $59.00 and maintained an Overweight rating.<\/p>\n<p><strong>Devon Energy (DVN)<\/strong> \u2014 Citigroup lowered its price target from $67.00 to $60.00 and maintained a Buy rating.<\/p>\n<p><strong>Ecolab (ECL)<\/strong> \u2014 Wells Fargo upgraded its rating from Equal Weight to Overweight and revised its price target from $315.00 to $380.00.<\/p>\n<p><strong>Okeanis Eco Tankers (ECO)<\/strong> \u2014 B. Riley Financial raised its price target from $100.00 to $120.00 and maintained a Buy rating.<\/p>\n<p><strong>Okeanis Eco Tankers (ECO)<\/strong> \u2014 Zacks Research upgraded its rating from Hold to Strong Buy.<\/p>\n<p><strong>Eagle Financial Services (EFSI)<\/strong> \u2014 Freedom Broker raised its price target from $43.00 to $46.20 and maintained a Hold rating.<\/p>\n<p><strong>eHealth (EHTH)<\/strong> \u2014 Zacks Research downgraded its rating from Sell (E) to Sell (E+).<\/p>\n<p><strong>enGene (ENGN)<\/strong> \u2014 Leerink Partners upgraded its rating from Market Perform to Outperform and has a price target of $5.00.<\/p>\n<p><strong>Enlight Renewable Energy (ENLT)<\/strong> \u2014 Truist Financial lowered its price target from $104.00 to $102.00 and maintained a Buy rating.<\/p>\n<p><strong>Enersys (ENS)<\/strong> \u2014 Oppenheimer lowered its price target from $250.00 to $210.00 and maintained an Outperform rating.<\/p>\n<p><strong>Enovix (ENVX)<\/strong> \u2014 Craig Hallum downgraded its rating from Buy to Hold and has a price target of $2.00.<\/p>\n<p><strong>Enovix (ENVX)<\/strong> \u2014 B. Riley Financial downgraded its rating from Buy to Neutral and revised its price target from $9.00 to $2.00.<\/p>\n<p><strong>Enovix (ENVX)<\/strong> \u2014 Oppenheimer downgraded its rating from Outperform to Market Perform.<\/p>\n<p><strong>EOG Resources (EOG)<\/strong> \u2014 Barclays raised its price target from $155.00 to $168.00 and maintained an Equal Weight rating.<\/p>\n<p><strong>Edgewell Personal Care (EPC)<\/strong> \u2014 Wells Fargo raised its price target from $30.00 to $32.00 and maintained an Overweight rating.<\/p>\n<p><strong>EPR Properties (EPR)<\/strong> \u2014 Citigroup reiterated a Market Outperform rating.<\/p>\n<p><strong>EPR Properties (EPR)<\/strong> \u2014 Citizens Jmp set a price target of $70.00, with no accompanying rating specified.<\/p>\n<p><strong>Equillium (EQ)<\/strong> \u2014 Raymond James Financial reiterated a Strong Buy rating.<\/p>\n<p><strong>Equillium (EQ)<\/strong> \u2014 Jefferies Financial Group set a price target of $4.00, with a Buy rating.<\/p>\n<p><strong>EquipmentShare.com (EQPT)<\/strong> \u2014 Citigroup raised its price target from $23.00 to $22.00 and maintained an Overweight rating.<\/p>\n<p><strong>enCore Energy (EU)<\/strong> \u2014 HC Wainwright has a price target of $1.50 and maintained a Buy rating.<\/p>\n<p><strong>enCore Energy (EU)<\/strong> \u2014 Canaccord Genuity Group downgraded its rating from Buy to Moderate Buy and has a price target of C$1.50.<\/p>\n<p><strong>Evommune (EVMN)<\/strong> \u2014 Needham &amp; Company LLC lowered its price target from $28.00 to $25.00 and maintained a Buy rating.<\/p>\n<p><strong>Exelixis (EXEL)<\/strong> \u2014 Morgan Stanley lowered its price target from $60.00 to $57.00 and maintained an Equal Weight rating.<\/p>\n<p><strong>National Vision (EYE)<\/strong> \u2014 UBS Group lowered its price target from $34.00 to $31.00 and maintained a Buy rating.<\/p>\n<p><strong>National Vision (EYE)<\/strong> \u2014 Barclays lowered its price target from $27.00 to $24.00 and maintained an Overweight rating.<\/p>\n<p><strong>EZCORP (EZPW)<\/strong> \u2014 Piper Sandler set a price target of $39.00, with no accompanying rating specified.<\/p>\n<p><strong>EZCORP (EZPW)<\/strong> \u2014 Canaccord Genuity Group lowered its price target from $45.00 to $44.00 and maintained a Buy rating.<\/p>\n<p><strong>EZCORP (EZPW)<\/strong> \u2014 Roth Capital reiterated a Buy rating with a price target of $40.00.<\/p>\n<p><strong>First American Financial (FAF)<\/strong> \u2014 Zacks Research downgraded its rating from Hold to Strong Sell.<\/p>\n<p><strong>Diamondback Energy (FANG)<\/strong> \u2014 Barclays raised its price target from $221.00 to $223.00 and maintained an Overweight rating.<\/p>\n<p><strong>Figure Technology Solutions (FIGR)<\/strong> \u2014 Needham &amp; Company LLC lowered its price target from $55.00 to $50.00 and maintained a Buy rating.<\/p>\n<p><strong>Flutter Entertainment (FLUT)<\/strong> \u2014 Zacks Research upgraded its rating from Strong Sell to Hold.<\/p>\n<p><strong>Firefly Aerospace (FLY)<\/strong> \u2014 Jefferies Financial Group lowered its price target from $35.00 to $30.00 and maintained a Buy rating.<\/p>\n<p><strong>Floor &amp; Decor (FND)<\/strong> \u2014 Evercore downgraded its rating from In-Line to Underperform and revised its price target from $55.00 to $45.00.<\/p>\n<p><strong>FOX (FOXA)<\/strong> \u2014 Morgan Stanley initiated coverage with an Overweight rating and set a price target of $90.00.<\/p>\n<p><strong>Forgent Power Solutions (FPS)<\/strong> \u2014 Sanford C. Bernstein lowered its price target from $48.00 to $33.00 and maintained an Outperform rating.<\/p>\n<p><strong>Forgent Power Solutions (FPS)<\/strong> \u2014 Robert W. Baird lowered its price target from $55.00 to $38.00 and maintained an Outperform rating.<\/p>\n<p><strong>Forgent Power Solutions (FPS)<\/strong> \u2014 TD Securities lowered its price target from $76.00 to $55.00 and maintained a Buy rating.<\/p>\n<p><strong>Forgent Power Solutions (FPS)<\/strong> \u2014 KeyCorp lowered its price target from $60.00 to $46.00 and maintained an Overweight rating.<\/p>\n<p><strong>Forgent Power Solutions (FPS)<\/strong> \u2014 Oppenheimer lowered its price target from $60.00 to $40.00 and maintained an Outperform rating.<\/p>\n<p><strong>fuboTV (FUBO)<\/strong> \u2014 B. Riley Financial lowered its price target from $18.00 to $16.00 and maintained a Buy rating.<\/p>\n<p><strong>First Watch Restaurant Group (FWRG)<\/strong> \u2014 Jefferies Financial Group set a price target of $20.00, with a Buy rating.<\/p>\n<p><strong>GAP (GAP)<\/strong> \u2014 Wells Fargo lowered its price target from $23.00 to $22.00 and maintained an Equal Weight rating.<\/p>\n<p><strong>Grid Dynamics (GDYN)<\/strong> \u2014 Zacks Research upgraded its rating from Hold to Strong Buy.<\/p>\n<p><strong>GH Research (GHRS)<\/strong> \u2014 Stifel set a price target of $38.00, with no accompanying rating specified.<\/p>\n<p><strong>Gilat Satellite Networks (GILT)<\/strong> \u2014 Freedom Broker lowered its price target from $18.40 to $13.30 and maintained a Buy rating.<\/p>\n<p><strong>Global-e Online (GLBE)<\/strong> \u2014 Piper Sandler reiterated an Overweight rating with a price target of $52.00.<\/p>\n<p><strong>Genmab A\/S (GMAB)<\/strong> \u2014 Morgan Stanley lowered its price target from $57.00 to $56.00 and maintained an Equal Weight rating.<\/p>\n<p><strong>Global Payments (GPN)<\/strong> \u2014 Raymond James Financial reiterated a Market Perform rating.<\/p>\n<p><strong>Green Brick Partners (GRBK)<\/strong> \u2014 BTIG Research reiterated a Neutral rating.<\/p>\n<p><strong>Granite Ridge Resources (GRNT)<\/strong> \u2014 Freedom Broker downgraded its rating from Buy to Hold and has a price target of $7.00.<\/p>\n<p><strong>Haemonetics (HAE)<\/strong> \u2014 Jefferies Financial Group initiated coverage with an Overweight rating and revised its price target from $22.00 to $24.00.<\/p>\n<p><strong>Horace Mann Educators (HMN)<\/strong> \u2014 Zacks Research upgraded its rating from Hold to Strong Buy.<\/p>\n<p><strong>Robinhood Markets (HOOD)<\/strong> \u2014 The Goldman Sachs Group lowered its price target from $128.00 to $115.00 and maintained a Buy rating.<\/p>\n<p><strong>HireQuest (HQI)<\/strong> \u2014 DA Davidson set a price target of $22.00, with no accompanying rating specified.<\/p>\n<p><strong>Harmony Biosciences (HRMY)<\/strong> \u2014 Zacks Research downgraded its rating from Strong Buy to Hold.<\/p>\n<p><strong>Heartflow (HTFL)<\/strong> \u2014 Wells Fargo raised its price target from $39.00 to $70.00 and maintained an Overweight rating.<\/p>\n<p><strong>Heartflow (HTFL)<\/strong> \u2014 Stifel raised its price target from $45.00 to $70.00 and maintained a Buy rating.<\/p>\n<p><strong>Heartflow (HTFL)<\/strong> \u2014 Canaccord Genuity Group raised its price target from $56.00 to $69.00 and maintained a Buy rating.<\/p>\n<p><strong>Heartflow (HTFL)<\/strong> \u2014 Robert W. Baird raised its price target from $56.00 to $68.00 and maintained an Outperform rating.<\/p>\n<p><strong>HubSpot (HUBS)<\/strong> \u2014 Needham &amp; Company LLC reiterated a Buy rating.<\/p>\n<p><strong>HubSpot (HUBS)<\/strong> \u2014 UBS Group set a price target of $190.00, with a Underperform rating.<\/p>\n<p><strong>Hancock Whitney (HWC)<\/strong> \u2014 Piper Sandler downgraded its rating from Overweight to Neutral and revised its price target from $88.00 to $71.50.<\/p>\n<p><strong>Hancock Whitney (HWC)<\/strong> \u2014 Stephens downgraded its rating from Strong Buy to Hold.<\/p>\n<p><strong>Hancock Whitney (HWC)<\/strong> \u2014 StoneX set a price target of $81.00, with no accompanying rating specified.<\/p>\n<p><strong>Hancock Whitney (HWC)<\/strong> \u2014 DA Davidson lowered its price target from $86.00 to $80.00 and maintained a Buy rating.<\/p>\n<p><strong>Installed Building Products (IBP)<\/strong> \u2014 Deutsche Bank upgraded its rating from Hold to Buy and revised its price target from $212.00 to $260.00.<\/p>\n<p><strong>i3 Verticals (IIIV)<\/strong> \u2014 Stephens initiated coverage with an Equal Weight rating and set a price target of $23.00.<\/p>\n<p><strong>ImageneBio (IMA)<\/strong> \u2014 HC Wainwright initiated coverage with a Strong Buy rating.<\/p>\n<p><strong>Immunocore (IMCR)<\/strong> \u2014 Morgan Stanley lowered its price target from $43.00 to $42.00 and maintained an Equal Weight rating.<\/p>\n<p><strong>Innio (INIO)<\/strong> \u2014 Piper Sandler initiated coverage with an Overweight rating and set a price target of $21.00.<\/p>\n<p><strong>INmune Bio (INMB)<\/strong> \u2014 Freedom Broker lowered its price target from $4.00 to $2.50 and maintained a Buy rating.<\/p>\n<p><strong>Jazz Pharmaceuticals (JAZZ)<\/strong> \u2014 Morgan Stanley raised its price target from $319.00 to $324.00 and maintained an Overweight rating.<\/p>\n<p><strong>Jefferson Capital (JCAP)<\/strong> \u2014 Jefferies Financial Group reiterated a Buy rating.<\/p>\n<p><strong>Keurig Dr Pepper (KDP)<\/strong> \u2014 Jefferies Financial Group reiterated a Hold rating.<\/p>\n<p><strong>Korn\/Ferry International (KFY)<\/strong> \u2014 Stephens initiated coverage with an Overweight rating and set a price target of $94.00.<\/p>\n<p><strong>Kodiak Gas Services (KGS)<\/strong> \u2014 Wells Fargo lowered its price target from $93.00 to $66.00 and maintained an Overweight rating.<\/p>\n<p><strong>KinderCare Learning Companies (KLC)<\/strong> \u2014 The Goldman Sachs Group lowered its price target from $3.90 to $3.40 and maintained a Neutral rating.<\/p>\n<p><strong>Coca-Cola (KO)<\/strong> \u2014 Bank of America reiterated a Buy rating.<\/p>\n<p><strong>Kodiak Sciences (KOD)<\/strong> \u2014 UBS Group raised its price target from $120.00 to $150.00 and maintained a Buy rating.<\/p>\n<p><strong>Kite Realty Group Trust (KRG)<\/strong> \u2014 National Bank Financial set a price target of $28.00, with no accompanying rating specified.<\/p>\n<p><strong>Kite Realty Group Trust (KRG)<\/strong> \u2014 Bank of America downgraded its rating from Buy to Neutral and revised its price target from $31.00 to $28.00.<\/p>\n<p><strong>Cyclerion Therapeutics (KRSA)<\/strong> \u2014 Wells Fargo initiated coverage with an Overweight rating and set a price target of $44.00.<\/p>\n<p><strong>Lithium Americas (LAC)<\/strong> \u2014 Canaccord Genuity Group downgraded its rating from Moderate Buy to Hold.<\/p>\n<p><strong>Lithium Americas (LAC)<\/strong> \u2014 JPMorgan lowered its price target from $6.00 to $5.00 and maintained an Overweight rating.<\/p>\n<p><strong>Legend Biotech (LEGN)<\/strong> \u2014 Evercore downgraded its rating from Outperform to In-Line and has a price target of $20.00.<\/p>\n<p><strong>Levi Strauss &amp; Co. (LEVI)<\/strong> \u2014 UBS Group reiterated a Buy rating.<\/p>\n<p><strong>LifeMD (LFMD)<\/strong> \u2014 Lake Street Capital lowered its price target from $5.00 to $3.00 and maintained a Buy rating.<\/p>\n<p><strong>LifeMD (LFMD)<\/strong> \u2014 Mizuho lowered its price target from $7.00 to $6.00 and maintained an Outperform rating.<\/p>\n<p><strong>Liftoff Mobile (LFTO)<\/strong> \u2014 Wells Fargo raised its price target from $21.00 to $27.00 and maintained an Overweight rating.<\/p>\n<p><strong>Liftoff Mobile (LFTO)<\/strong> \u2014 Piper Sandler raised its price target from $19.00 to $24.00 and maintained a Neutral rating.<\/p>\n<p><strong>Liftoff Mobile (LFTO)<\/strong> \u2014 RBC raised its price target from $35.00 to $38.00 and maintained an Outperform rating.<\/p>\n<p><strong>Liftoff Mobile (LFTO)<\/strong> \u2014 Barclays lowered its price target from $34.00 to $30.00 and maintained an Overweight rating.<\/p>\n<p><strong>Liftoff Mobile (LFTO)<\/strong> \u2014 Freedom Broker upgraded its rating from Hold to Buy and has a price target of $27.00.<\/p>\n<p><strong>Liftoff Mobile (LFTO)<\/strong> \u2014 Freedom Capital upgraded its rating from Hold to Buy and has a price target of $27.00.<\/p>\n<p><strong>Liftoff Mobile (LFTO)<\/strong> \u2014 BTIG Research raised its price target from $27.00 to $31.00 and maintained a Buy rating.<\/p>\n<p><strong>Lifevantage (LFVN)<\/strong> \u2014 Freedom Broker lowered its price target from $9.00 to $8.00 and maintained a Buy rating.<\/p>\n<p><strong>Lifevantage (LFVN)<\/strong> \u2014 UBS Group set a price target of $8.00, with no accompanying rating specified.<\/p>\n<p><strong>LGN (LGN)<\/strong> \u2014 Sanford C. Bernstein reiterated an Outperform rating.<\/p>\n<p><strong>LGN (LGN)<\/strong> \u2014 BTIG Research lowered its price target from $100.00 to $60.00 and maintained a Buy rating.<\/p>\n<p><strong>Lineage (LINE)<\/strong> \u2014 Piper Sandler raised its price target from $36.00 to $37.00 and maintained a Neutral rating.<\/p>\n<p><strong>Lakefront Biotherapeutics American Depositary Shares (LKFT)<\/strong> \u2014 TD Securities initiated coverage with a Strong Buy rating.<\/p>\n<p><strong>Lowe&#8217;s Companies (LOW)<\/strong> \u2014 Evercore downgraded its rating from Hold to Strong Sell.<\/p>\n<p><strong>Lowe&#8217;s Companies (LOW)<\/strong> \u2014 Stifel downgraded its rating from Hold to Sell and revised its price target from $195.00 to $190.00.<\/p>\n<p><strong>Liquidia (LQDA)<\/strong> \u2014 HC Wainwright initiated coverage with a Buy rating and set a price target of $76.00.<\/p>\n<p><strong>Intuitive Machines (LUNR)<\/strong> \u2014 Roth Capital lowered its price target from $30.00 to $20.00 and maintained a Buy rating.<\/p>\n<p><strong>Lyell Immunopharma (LYEL)<\/strong> \u2014 HC Wainwright lowered its price target from $45.00 to $39.00 and maintained a Buy rating.<\/p>\n<p><strong>Mobility Global (MBGL)<\/strong> \u2014 JPMorgan raised its price target from $21.00 to $25.00 and maintained a Neutral rating.<\/p>\n<p><strong>Mobility Global (MBGL)<\/strong> \u2014 RBC raised its price target from $23.00 to $25.00 and maintained a Sector Perform rating.<\/p>\n<p><strong>Mobility Global (MBGL)<\/strong> \u2014 Barclays raised its price target from $23.00 to $25.00 and maintained an Equal Weight rating.<\/p>\n<p><strong>Mobility Global (MBGL)<\/strong> \u2014 Robert W. Baird raised its price target from $22.00 to $26.00 and maintained a Neutral rating.<\/p>\n<p><strong>Mobility Global (MBGL)<\/strong> \u2014 Wells Fargo raised its price target from $23.00 to $29.00 and maintained an Overweight rating.<\/p>\n<p><strong>Mondelez International (MDLZ)<\/strong> \u2014 BTIG Research reiterated a Buy rating.<\/p>\n<p><strong>MiniMed Group (MMED)<\/strong> \u2014 Barclays lowered its price target from $22.00 to $20.00 and maintained an Equal Weight rating.<\/p>\n<p><strong>monday.com (MNDY)<\/strong> \u2014 Zacks Research upgraded its rating from Hold to Strong Buy.<\/p>\n<p><strong>Marathon Petroleum (MPC)<\/strong> \u2014 Zacks Research downgraded its rating from Strong Buy to Hold.<\/p>\n<p><strong>Marathon Petroleum (MPC)<\/strong> \u2014 Mizuho lowered its price target from $457.00 to $440.00 and maintained a Neutral rating.<\/p>\n<p><strong>MP Materials (MP)<\/strong> \u2014 Zacks Research upgraded its rating from Strong Sell to Hold.<\/p>\n<p><strong>Marker Therapeutics (MRKR)<\/strong> \u2014 Zacks Research downgraded its rating from Strong Buy to Hold.<\/p>\n<p><strong>Marsh &amp; McLennan Companies (MRSH)<\/strong> \u2014 Mizuho raised its price target from $200.00 to $218.00 and maintained a Neutral rating.<\/p>\n<p><strong>Murphy Oil (MUR)<\/strong> \u2014 Barclays raised its price target from $34.00 to $35.00 and maintained an Underweight rating.<\/p>\n<p><strong>SOLV Energy (MWH)<\/strong> \u2014 JPMorgan raised its price target from $34.00 to $36.00 and maintained an Overweight rating.<\/p>\n<p><strong>Nebius Group (NBIS)<\/strong> \u2014 DA Davidson lowered its price target from $250.00 to $125.00 and maintained a Neutral rating.<\/p>\n<p><strong>Nebius Group (NBIS)<\/strong> \u2014 Robert W. Baird lowered its price target from $340.00 to $200.00 and maintained an Outperform rating.<\/p>\n<p><strong>Nebius Group (NBIS)<\/strong> \u2014 Rosenblatt Securities reiterated a Buy rating with a price target of $304.00.<\/p>\n<p><strong>Nebius Group (NBIS)<\/strong> \u2014 Truist Financial reiterated a Buy rating with a price target of $355.00 ? $245.00.<\/p>\n<p><strong>Neurocrine Biosciences (NBIX)<\/strong> \u2014 Morgan Stanley raised its price target from $185.00 to $191.00 and maintained an Equal Weight rating.<\/p>\n<p><strong>Nexxen International (NEXN)<\/strong> \u2014 RBC raised its price target from $13.00 to $14.00 and maintained an Outperform rating.<\/p>\n<p><strong>National Health Investors (NHI)<\/strong> \u2014 Bank of America downgraded its rating from Buy to Underperform and revised its price target from $86.00 to $67.00.<\/p>\n<p><strong>NIQ Global Intelligence (NIQ)<\/strong> \u2014 Needham &amp; Company LLC raised its price target from $21.00 to $24.00 and maintained a Buy rating.<\/p>\n<p><strong>NIQ Global Intelligence (NIQ)<\/strong> \u2014 Barclays raised its price target from $24.00 to $25.00 and maintained an Overweight rating.<\/p>\n<p><strong>NIQ Global Intelligence (NIQ)<\/strong> \u2014 RBC raised its price target from $17.00 to $23.00 and maintained an Outperform rating.<\/p>\n<p><strong>NIQ Global Intelligence (NIQ)<\/strong> \u2014 Wells Fargo raised its price target from $16.50 to $22.00 and maintained an Overweight rating.<\/p>\n<p><strong>NIQ Global Intelligence (NIQ)<\/strong> \u2014 Bank of America set a price target of $23.00, with a Buy rating.<\/p>\n<p><strong>NIKE (NKE)<\/strong> \u2014 Piper Sandler reiterated a Neutral rating.<\/p>\n<p><strong>Newsmax (NMAX)<\/strong> \u2014 Noble Financial initiated coverage with a Strong Buy rating.<\/p>\n<p><strong>Newsmax (NMAX)<\/strong> \u2014 Freedom Capital upgraded its rating from Hold to Buy and has a price target of $10.00.<\/p>\n<p><strong>Newsmax (NMAX)<\/strong> \u2014 Freedom Broker upgraded its rating from Hold to Buy and has a price target of $10.00.<\/p>\n<p><strong>Nouveau Monde Graphite (NMG)<\/strong> \u2014 Freedom Broker upgraded its rating from Hold to Buy and revised its price target from $1.48 to $1.64.<\/p>\n<p><strong>NMI (NMIH)<\/strong> \u2014 BTIG Research lowered its price target from $54.00 to $52.00 and maintained a Buy rating.<\/p>\n<p><strong>NeuroPace (NPCE)<\/strong> \u2014 Cantor Fitzgerald lowered its price target from $21.00 to $12.00 and maintained an Overweight rating.<\/p>\n<p><strong>NeuroPace (NPCE)<\/strong> \u2014 KeyCorp lowered its price target from $18.00 to $14.00 and maintained an Overweight rating.<\/p>\n<p><strong>NeuroPace (NPCE)<\/strong> \u2014 Wells Fargo downgraded its rating from Overweight to Equal Weight and revised its price target from $19.00 to $9.00.<\/p>\n<p><strong>NeuroPace (NPCE)<\/strong> \u2014 JPMorgan downgraded its rating from Overweight to Neutral and revised its price target from $20.00 to $9.00.<\/p>\n<p><strong>NeuroPace (NPCE)<\/strong> \u2014 Leerink Partners downgraded its rating from Outperform to Market Perform and has a price target of $7.00.<\/p>\n<p><strong>Neptune Insurance (NP)<\/strong> \u2014 Mizuho lowered its price target from $33.00 to $31.00 and maintained a Neutral rating.<\/p>\n<p><strong>NerdWallet (NRDS)<\/strong> \u2014 Oppenheimer downgraded its rating from Outperform to Market Perform.<\/p>\n<p><strong>Intellia Therapeutics (NTLA)<\/strong> \u2014 Citigroup reiterated a Market Outperform rating.<\/p>\n<p><strong>Intellia Therapeutics (NTLA)<\/strong> \u2014 Citizens Jmp set a price target of $30.00, with no accompanying rating specified.<\/p>\n<p><strong>Netskope (NTSK)<\/strong> \u2014 Morgan Stanley downgraded its rating from Overweight to Equal Weight and revised its price target from $16.00 to $24.00.<\/p>\n<p><strong>NetSol Technologies (NTWK)<\/strong> \u2014 Noble Financial initiated coverage with a Strong Buy rating.<\/p>\n<p><strong>New Era Energy &amp; Digital (NUAI)<\/strong> \u2014 Roth Capital raised its price target from $7.00 to $17.00 and maintained a Buy rating.<\/p>\n<p><strong>NU (NU)<\/strong> \u2014 Needham &amp; Company LLC reiterated a Buy rating with a price target of $19.00.<\/p>\n<p><strong>NVIDIA (NVDA)<\/strong> \u2014 Barclays lowered its price target from $275.00 to $210.00 and maintained an Overweight rating.<\/p>\n<p><strong>NVIDIA (NVDA)<\/strong> \u2014 HSBC downgraded its rating from Buy to Hold and has a price target of $170.00.<\/p>\n<p><strong>NVIDIA (NVDA)<\/strong> \u2014 GF Securities downgraded its rating from Buy to Hold and has a price target of $188.00.<\/p>\n<p><strong>NVIDIA (NVDA)<\/strong> \u2014 Rosenblatt Securities lowered its price target from $390.00 to $300.00 and maintained a Buy rating.<\/p>\n<p><strong>NVIDIA (NVDA)<\/strong> \u2014 Wells Fargo downgraded its rating from Strong Buy to Hold.<\/p>\n<p><strong>Orchestra BioMed (OBIO)<\/strong> \u2014 HC Wainwright raised its price target from $10.00 to $12.00 and maintained a Buy rating.<\/p>\n<p><strong>Orchestra BioMed (OBIO)<\/strong> \u2014 BTIG Research raised its price target from $10.00 to $12.00 and maintained a Buy rating.<\/p>\n<p><strong>Once Upon A Farm (OFRM)<\/strong> \u2014 TD Securities lowered its price target from $13.00 to $10.00 and maintained a Hold rating.<\/p>\n<p><strong>Oklo (OKLO)<\/strong> \u2014 Truist Financial lowered its price target from $31.00 to $28.00 and maintained a Hold rating.<\/p>\n<p><strong>Omnicell (OMCL)<\/strong> \u2014 BTIG Research reiterated a Neutral rating.<\/p>\n<p><strong>BeOne Medicines (ONC)<\/strong> \u2014 Morgan Stanley raised its price target from $465.00 to $476.00 and maintained an Overweight rating.<\/p>\n<p><strong>Ondas (ONDS)<\/strong> \u2014 Needham &amp; Company LLC lowered its price target from $19.00 to $14.00 and maintained a Buy rating.<\/p>\n<p><strong>Ondas (ONDS)<\/strong> \u2014 Rothschild &amp; Co Redburn set a price target of $14.00, with no accompanying rating specified.<\/p>\n<p><strong>Ondas (ONDS)<\/strong> \u2014 Citigroup reiterated a Market Outperform rating.<\/p>\n<p><strong>Ondas (ONDS)<\/strong> \u2014 Lake Street Capital lowered its price target from $19.00 to $14.00 and maintained a Buy rating.<\/p>\n<p><strong>OR Royalties (OR)<\/strong> \u2014 Raymond James Financial issued a target update without a quoted target, with a Sell (E-) rating.<\/p>\n<p><strong>Ovintiv (OVV)<\/strong> \u2014 Citigroup raised its price target from $68.00 to $74.00 and maintained a Buy rating.<\/p>\n<p><strong>Ovintiv (OVV)<\/strong> \u2014 Barclays raised its price target from $80.00 to $85.00 and maintained an Overweight rating.<\/p>\n<p><strong>Occidental Petroleum (OXY)<\/strong> \u2014 Barclays raised its price target from $71.00 to $73.00 and maintained an Overweight rating.<\/p>\n<p><strong>Proficient Auto Logistics (PAL)<\/strong> \u2014 Stifel lowered its price target from $10.00 to $9.00 and maintained a Buy rating.<\/p>\n<p><strong>Proficient Auto Logistics (PAL)<\/strong> \u2014 Barrington Research lowered its price target from $12.00 to $9.00 and maintained an Outperform rating.<\/p>\n<p><strong>Palo Alto Networks (PANW)<\/strong> \u2014 KeyCorp upgraded its rating from Sector Weight to Overweight and has a price target of $380.00.<\/p>\n<p><strong>PAR Technology (PAR)<\/strong> \u2014 Stephens initiated coverage with an Equal Weight rating and set a price target of $25.00.<\/p>\n<p><strong>Par Pacific (PARR)<\/strong> \u2014 Mizuho lowered its price target from $91.00 to $80.00 and maintained a Neutral rating.<\/p>\n<p><strong>PepGen (PEPG)<\/strong> \u2014 Guggenheim raised its price target from $7.00 to $15.00 and maintained a Buy rating.<\/p>\n<p><strong>PepsiCo (PEP)<\/strong> \u2014 Sanford C. Bernstein reiterated an Outperform rating with a price target of $144.00.<\/p>\n<p><strong>Fidelis Insurance (PLGO)<\/strong> \u2014 Keefe, Bruyette &amp; Woods raised its price target from $28.00 to $32.00 and maintained an Outperform rating.<\/p>\n<p><strong>Douglas Dynamics (PLOW)<\/strong> \u2014 Freedom Broker lowered its price target from $56.00 to $55.00 and maintained a Buy rating.<\/p>\n<p><strong>Plexus (PLXS)<\/strong> \u2014 Raymond James Financial reiterated an Outperform rating.<\/p>\n<p><strong>Power Integrations (POWI)<\/strong> \u2014 Roth Capital initiated coverage with a Buy rating and set a price target of $52.00.<\/p>\n<p><strong>Perpetua Resources (PPTA)<\/strong> \u2014 Zacks Research upgraded its rating from Strong Sell to Hold.<\/p>\n<p><strong>Porch Group (PRCH)<\/strong> \u2014 Zacks Research downgraded its rating from Strong Buy to Hold.<\/p>\n<p><strong>Perimeter Solutions (PRM)<\/strong> \u2014 Zacks Research downgraded its rating from Hold to Strong Sell.<\/p>\n<p><strong>ProQR Therapeutics (PRQR)<\/strong> \u2014 Citigroup reiterated a Market Outperform rating.<\/p>\n<p><strong>ProQR Therapeutics (PRQR)<\/strong> \u2014 Raymond James Financial reiterated a Strong Buy rating.<\/p>\n<p><strong>Paysafe (PSFE)<\/strong> \u2014 UBS Group lowered its price target from $7.00 to $3.50 and maintained a Sell rating.<\/p>\n<p><strong>Paysafe (PSFE)<\/strong> \u2014 RBC lowered its price target from $9.00 to $6.00 and maintained a Sector Perform rating.<\/p>\n<p><strong>Paysafe (PSFE)<\/strong> \u2014 BTIG Research downgraded its rating from Buy to Neutral.<\/p>\n<p><strong>Qiagen (QGEN)<\/strong> \u2014 UBS Group raised its price target from $48.00 to $50.00 and maintained a Neutral rating.<\/p>\n<p><strong>QuinStreet (QNST)<\/strong> \u2014 Stephens changed its rating from Hold (C-) to Hold (C).<\/p>\n<p><strong>QXO (QXO)<\/strong> \u2014 DA Davidson lowered its price target from $20.00 to $19.00 and maintained a Buy rating.<\/p>\n<p><strong>QXO (QXO)<\/strong> \u2014 KeyCorp lowered its price target from $28.00 to $19.00 and maintained an Overweight rating.<\/p>\n<p><strong>Ralliant (RAL)<\/strong> \u2014 Zacks Research upgraded its rating from Hold to Strong Buy.<\/p>\n<p><strong>Roblox (RBLX)<\/strong> \u2014 BTIG Research upgraded its rating from Strong Sell to Hold.<\/p>\n<p><strong>Roblox (RBLX)<\/strong> \u2014 Citigroup downgraded its rating from Buy to Neutral and has a price target of $55.00.<\/p>\n<p><strong>RingCentral (RNG)<\/strong> \u2014 Raymond James Financial set a price target of $8.00, with no accompanying rating specified.<\/p>\n<p><strong>Ross Stores (ROST)<\/strong> \u2014 Wells Fargo lowered its price target from $248.00 to $242.00 and maintained an Equal Weight rating.<\/p>\n<p><strong>Repay (RPAY)<\/strong> \u2014 Stephens initiated coverage with an Equal Weight rating and set a price target of $5.00.<\/p>\n<p><strong>Range Resources (RRC)<\/strong> \u2014 Barclays raised its price target from $42.00 to $67.00 and maintained an Equal Weight rating.<\/p>\n<p><strong>Riskified (RSKD)<\/strong> \u2014 The Goldman Sachs Group raised its price target from $7.50 to $9.00 and maintained a Sell rating.<\/p>\n<p><strong>Sunrun (RUN)<\/strong> \u2014 Wells Fargo lowered its price target from $17.00 to $14.00 and maintained an Overweight rating.<\/p>\n<p><strong>Revolution Medicines (RVMD)<\/strong> \u2014 Morgan Stanley lowered its price target from $272.00 to $247.00 and maintained an Overweight rating.<\/p>\n<p><strong>Ryan Specialty (RYAN)<\/strong> \u2014 Mizuho raised its price target from $40.00 to $48.00 and maintained a Neutral rating.<\/p>\n<p><strong>SBC Medical Group (SBC)<\/strong> \u2014 BTIG Research raised its price target from $8.00 to $10.00 and maintained a Buy rating.<\/p>\n<p><strong>Sally Beauty (SBH)<\/strong> \u2014 TD Securities raised its price target from $19.00 to $22.00 and maintained a Buy rating.<\/p>\n<p><strong>Sally Beauty (SBH)<\/strong> \u2014 RBC set a price target of $22.00, with no accompanying rating specified.<\/p>\n<p><strong>Service Corporation International (SCI)<\/strong> \u2014 Stephens changed its rating from Sell (E+) to Sell (D-).<\/p>\n<p><strong>Seadrill (SDRL)<\/strong> \u2014 Citigroup raised its price target from $54.00 to $55.00 and maintained a Neutral rating.<\/p>\n<p><strong>Serve Robotics (SERV)<\/strong> \u2014 Freedom Capital downgraded its rating from Buy to Hold and has a price target of $3.50.<\/p>\n<p><strong>Serve Robotics (SERV)<\/strong> \u2014 Freedom Broker downgraded its rating from Buy to Hold and has a price target of $3.50.<\/p>\n<p><strong>SEA (SE)<\/strong> \u2014 JPMorgan lowered its price target from $149.00 to $132.00 and maintained an Overweight rating.<\/p>\n<p><strong>Saga Communications (SGA)<\/strong> \u2014 Noble Financial initiated coverage with a Hold rating.<\/p>\n<p><strong>Sagimet Biosciences (SGMT)<\/strong> \u2014 Wells Fargo set a price target of $27.00, with no accompanying rating specified.<\/p>\n<p><strong>Sagimet Biosciences (SGMT)<\/strong> \u2014 Citigroup reiterated a Market Outperform rating.<\/p>\n<p><strong>Sagimet Biosciences (SGMT)<\/strong> \u2014 The Goldman Sachs Group reiterated a Sell rating.<\/p>\n<p><strong>Sagimet Biosciences (SGMT)<\/strong> \u2014 Canaccord Genuity Group lowered its price target from $56.00 to $50.00 and maintained a Buy rating.<\/p>\n<p><strong>Spyglass Pharma (SGP)<\/strong> \u2014 Stifel raised its price target from $42.00 to $44.00 and maintained a Buy rating.<\/p>\n<p><strong>Spyglass Pharma (SGP)<\/strong> \u2014 Citigroup raised its price target from $42.00 to $45.00 and maintained a Buy rating.<\/p>\n<p><strong>SiTime (SITM)<\/strong> \u2014 Zacks Research upgraded its rating from Hold to Strong Buy.<\/p>\n<p><strong>Snail (SNAL)<\/strong> \u2014 Noble Financial changed its rating from Sell (E+) to Sell (D-).<\/p>\n<p><strong>Spectrum Brands (SPB)<\/strong> \u2014 Raymond James Financial reiterated a Market Perform rating.<\/p>\n<p><strong>Spectrum Brands (SPB)<\/strong> \u2014 Canaccord Genuity Group lowered its price target from $110.00 to $105.00 and maintained a Buy rating.<\/p>\n<p><strong>SpaceX (SPCX)<\/strong> \u2014 KeyCorp reiterated a Sector Weight rating.<\/p>\n<p><strong>Spire Global (SPIR)<\/strong> \u2014 Canaccord Genuity Group lowered its price target from $22.50 to $21.50 and maintained a Buy rating.<\/p>\n<p><strong>Sound Point Meridian Capital (SPMC)<\/strong> \u2014 B. Riley Financial lowered its price target from $10.00 to $6.50 and maintained a Neutral rating.<\/p>\n<p><strong>Standard Nuclear (STDN)<\/strong> \u2014 Needham &amp; Company LLC reiterated a Buy rating.<\/p>\n<p><strong>STERIS (STE)<\/strong> \u2014 Jefferies Financial Group upgraded its rating from Hold to Buy and revised its price target from $232.00 to $305.00.<\/p>\n<p><strong>STERIS (STE)<\/strong> \u2014 Morgan Stanley upgraded its rating from Overweight to Buy.<\/p>\n<p><strong>Sutro Biopharma (STRO)<\/strong> \u2014 Barclays raised its price target from $56.00 to $57.00 and maintained an Overweight rating.<\/p>\n<p><strong>STUB (STUB)<\/strong> \u2014 TD Securities lowered its price target from $12.00 to $10.00 and maintained a Buy rating.<\/p>\n<p><strong>Telephone and Data Systems (TDS)<\/strong> \u2014 Citigroup lowered its price target from $47.00 to $44.00 and maintained a Buy rating.<\/p>\n<p><strong>Tecnoglass (TGLS)<\/strong> \u2014 B. Riley Financial raised its price target from $55.00 to $63.00 and maintained a Buy rating.<\/p>\n<p><strong>TIM (TIMB)<\/strong> \u2014 Barclays raised its price target from $20.00 to $22.00 and maintained an Equal Weight rating.<\/p>\n<p><strong>TJX Companies (TJX)<\/strong> \u2014 Wells Fargo lowered its price target from $140.00 to $135.00 and maintained an Equal Weight rating.<\/p>\n<p><strong>TJX Companies (TJX)<\/strong> \u2014 Gordon Haskett downgraded its rating from Accumulate to Hold and has a price target of $130.00.<\/p>\n<p><strong>TMC the metals (TMC)<\/strong> \u2014 HC Wainwright lowered its price target from $11.75 to $5.50 and maintained a Buy rating.<\/p>\n<p><strong>Teekay Tankers (TNK)<\/strong> \u2014 Zacks Research upgraded its rating from Hold to Strong Buy.<\/p>\n<p><strong>Trustmark (TRMK)<\/strong> \u2014 Brean Capital downgraded its rating from Strong Buy to Hold.<\/p>\n<p><strong>Terreno Realty (TRNO)<\/strong> \u2014 Piper Sandler reiterated an Overweight rating.<\/p>\n<p><strong>Tractor Supply (TSCO)<\/strong> \u2014 Stephens downgraded its rating from Hold to Underperform.<\/p>\n<p><strong>Tractor Supply (TSCO)<\/strong> \u2014 Evercore downgraded its rating from Outperform to In-Line and revised its price target from $40.00 to $38.00.<\/p>\n<p><strong>Tesla (TSLA)<\/strong> \u2014 Glj Research reiterated a Sell rating.<\/p>\n<p><strong>Tenaris (TS)<\/strong> \u2014 Stifel raised its price target from $57.00 to $67.00 and maintained a Buy rating.<\/p>\n<p><strong>Tetra Tech (TTEK)<\/strong> \u2014 KeyCorp raised its price target from $41.00 to $42.00 and maintained an Overweight rating.<\/p>\n<p><strong>Twist Bioscience (TWST)<\/strong> \u2014 Robert W. Baird lowered its price target from $187.00 to $135.00 and maintained an Outperform rating.<\/p>\n<p><strong>Twist Bioscience (TWST)<\/strong> \u2014 TD Securities lowered its price target from $190.00 to $137.00 and maintained a Buy rating.<\/p>\n<p><strong>Twist Bioscience (TWST)<\/strong> \u2014 Canaccord Genuity Group lowered its price target from $205.00 to $150.00 and maintained a Buy rating.<\/p>\n<p><strong>Twist Bioscience (TWST)<\/strong> \u2014 Leerink Partners lowered its price target from $190.00 to $175.00 and maintained an Outperform rating.<\/p>\n<p><strong>Twist Bioscience (TWST)<\/strong> \u2014 RBC set a price target of $137.00, with no accompanying rating specified.<\/p>\n<p><strong>United States Antimony (UAMY)<\/strong> \u2014 HC Wainwright lowered its price target from $9.25 to $6.50 and maintained a Buy rating.<\/p>\n<p><strong>Ultra Clean (UCTT)<\/strong> \u2014 UBS Group changed its rating from Buy to Positive.<\/p>\n<p><strong>Ultra Clean (UCTT)<\/strong> \u2014 Barclays initiated coverage with an Equal Weight rating and set a price target of $65.00.<\/p>\n<p><strong>Ultrapar Participacoes (UGP)<\/strong> \u2014 Zacks Research downgraded its rating from Strong Buy to Hold.<\/p>\n<p><strong>Unisys (UIS)<\/strong> \u2014 Zacks Research upgraded its rating from Strong Sell to Hold.<\/p>\n<p><strong>Urban Outfitters (URBN)<\/strong> \u2014 UBS Group reiterated a Neutral rating.<\/p>\n<p><strong>U.S. Physical Therapy (USPH)<\/strong> \u2014 Barrington Research has a price target of $72.00 and maintained an Overweight rating.<\/p>\n<p><strong>Visteon (VC)<\/strong> \u2014 RBC raised its price target from $100.00 to $102.00 and maintained an Outperform rating.<\/p>\n<p><strong>Versigent (VGNT)<\/strong> \u2014 Zacks Research upgraded its rating from Strong Sell to Hold.<\/p>\n<p><strong>Controladora Vuela Compania de Aviacion (VLRS)<\/strong> \u2014 Zacks Research upgraded its rating from Strong Sell to Hold.<\/p>\n<p><strong>Vox Royalty (VOXR)<\/strong> \u2014 Roth Capital reiterated a Buy rating with a price target of $8.50 ? $8.25.<\/p>\n<p><strong>VirTra (VTSI)<\/strong> \u2014 Roth Capital reiterated a Buy rating with a price target of $7.50.<\/p>\n<p><strong>Vylor (VYLR)<\/strong> \u2014 UBS Group lowered its price target from $89.00 to $87.00 and maintained a Buy rating.<\/p>\n<p><strong>NCR Voyix (VYX)<\/strong> \u2014 Stephens initiated coverage with an Equal Weight rating and set a price target of $12.00.<\/p>\n<p><strong>Warner Music Group (WMG)<\/strong> \u2014 Morgan Stanley raised its price target from $36.00 to $39.00 and maintained an Overweight rating.<\/p>\n<p><strong>Advanced Drainage Systems (WMS)<\/strong> \u2014 Jefferies Financial Group initiated coverage with a Strong Buy rating.<\/p>\n<p><strong>Walmart (WMT)<\/strong> \u2014 Wells Fargo changed its rating from Sell (E+) to Sell (D-).<\/p>\n<p><strong>Wise Group (WSE)<\/strong> \u2014 UBS Group raised its price target from $17.25 to $18.00 and maintained a Buy rating.<\/p>\n<p><strong>Willis Towers Watson Public (WTW)<\/strong> \u2014 Mizuho raised its price target from $370.00 to $384.00 and maintained an Outperform rating.<\/p>\n<p><strong>Westwater Resources (WWR)<\/strong> \u2014 HC Wainwright lowered its price target from $1.50 to $1.25 and maintained a Buy rating.<\/p>\n<p><strong>Wolverine World Wide (WWW)<\/strong> \u2014 UBS Group raised its price target from $31.00 to $33.00 and maintained a Buy rating.<\/p>\n<p><strong>Wolverine World Wide (WWW)<\/strong> \u2014 Oppenheimer maintained a Market Perform rating.<\/p>\n<p><strong>Wolverine World Wide (WWW)<\/strong> \u2014 Williams Trading set a price target of $21.00, with no accompanying rating specified.<\/p>\n<p><strong>Wolverine World Wide (WWW)<\/strong> \u2014 Robert W. Baird raised its price target from $26.00 to $27.00 and maintained an Outperform rating.<\/p>\n<p><strong>Wolverine World Wide (WWW)<\/strong> \u2014 Stifel raised its price target from $26.00 to $28.00 and maintained a Buy rating.<\/p>\n<p><strong>Wolverine World Wide (WWW)<\/strong> \u2014 KeyCorp raised its price target from $25.00 to $27.00 and maintained an Overweight rating.<\/p>\n<p><strong>X-Energy (XE)<\/strong> \u2014 TD Securities lowered its price target from $35.00 to $25.00 and maintained a Buy rating.<\/p>\n<p><strong>Xometry (XMTR)<\/strong> \u2014 Rosenblatt Securities raised its price target from $130.00 to $140.00 and maintained a Buy rating.<\/p>\n<p><strong>ExxonMobil (XOM)<\/strong> \u2014 Barclays raised its price target from $200.00 to $206.00 and maintained an Overweight rating.<\/p>\n<p><strong>Global Medical REIT (XRN)<\/strong> \u2014 Zacks Research downgraded its rating from Hold to Strong Sell.<\/p>\n<p><strong>Block (XYZ)<\/strong> \u2014 Freedom Broker raised its price target from $105.00 to $115.00 and maintained a Buy rating.<\/p>\n<p><strong>YETI (YETI)<\/strong> \u2014 Citigroup lowered its price target from $53.00 to $50.00 and maintained a Buy rating.<\/p>\n<p><strong>YETI (YETI)<\/strong> \u2014 KeyCorp lowered its price target from $57.00 to $49.00 and maintained an Overweight rating.<\/p>\n<p><strong>YETI (YETI)<\/strong> \u2014 Canaccord Genuity Group lowered its price target from $46.00 to $42.00 and maintained a Hold rating.<\/p>\n<p><strong>YETI (YETI)<\/strong> \u2014 Roth Capital reiterated a Buy rating with a price target of $62.00 ? $52.00.<\/p>\n<p><strong>YETI (YETI)<\/strong> \u2014 Stifel lowered its price target from $50.00 to $48.00 and maintained a Buy rating.<\/p>\n<p><strong>YETI (YETI)<\/strong> \u2014 Robert W. Baird lowered its price target from $57.00 to $50.00 and maintained an Outperform rating.<\/p>\n<p><strong>YETI (YETI)<\/strong> \u2014 Piper Sandler downgraded its rating from Overweight to Neutral and revised its price target from $58.00 to $39.00.<\/p>\n<p><strong>York Space Systems (YSS)<\/strong> \u2014 Needham &amp; Company LLC lowered its price target from $18.00 to $10.00 and maintained a Buy rating.<\/p>\n<p><strong>York Space Systems (YSS)<\/strong> \u2014 Piper Sandler lowered its price target from $8.00 to $7.00 and maintained a Neutral rating.<\/p>\n<p><strong>York Space Systems (YSS)<\/strong> \u2014 Jefferies Financial Group downgraded its rating from Buy to Hold and revised its price target from $15.00 to $6.00.<\/p>\n<p><strong>Yesway (YSWY)<\/strong> \u2014 Raymond James Financial reiterated an Outperform rating.<\/p>\n<p><strong>Zeta Global (ZETA)<\/strong> \u2014 Freedom Broker changed its rating from Sell (E+) to Sell (D-).<\/p>\n<p><strong>Zevra Therapeutics (ZVRA)<\/strong> \u2014 BTIG Research lowered its price target from $24.00 to $21.00 and maintained a Buy rating.<\/p>\n<p><strong>Zevra Therapeutics (ZVRA)<\/strong> \u2014 Cantor Fitzgerald lowered its price target from $25.00 to $19.00 and maintained an Overweight rating.<\/p>\n<p><strong>Zymeworks (ZYME)<\/strong> \u2014 Citizens Jmp raised its price target from $32.00 to $39.00 and maintained a Market Outperform rating.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Analyst Ratings Updates (USA) Applied Aerospace &amp; Defense (AADX) \u2014 Guggenheim lowered its price target from $30.00 to $15.00 and maintained a Buy rating.&hellip;<\/p>\n","protected":false},"author":3,"featured_media":28535,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-77144","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v19.4 (Yoast SEO v21.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>American Analyst Ratings Updates: November 13th, 2026 | Stock Target Advisor<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-13th-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"American Analyst Ratings Updates: November 13th, 2026\" \/>\n<meta property=\"og:description\" content=\"Analyst Ratings Updates (USA) Applied Aerospace &amp; Defense (AADX) \u2014 Guggenheim lowered its price target from $30.00 to $15.00 and maintained a Buy rating.&hellip;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-13th-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-17T19:38:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2023\/02\/Desktop-1-6-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"STA Research\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"STA Research\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"33 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-13th-2026\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-13th-2026\/\"},\"author\":{\"name\":\"STA Research\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae\"},\"headline\":\"American Analyst Ratings Updates: November 13th, 2026\",\"datePublished\":\"2026-11-17T19:38:49+00:00\",\"dateModified\":\"2026-11-17T19:38:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-13th-2026\/\"},\"wordCount\":6874,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News &amp; Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-13th-2026\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-13th-2026\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-13th-2026\/\",\"name\":\"American Analyst Ratings Updates: November 13th, 2026 | Stock Target Advisor\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2026-11-17T19:38:49+00:00\",\"dateModified\":\"2026-11-17T19:38:49+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-13th-2026\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-13th-2026\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-13th-2026\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"American Analyst Ratings Updates: November 13th, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae\",\"name\":\"STA Research\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g\",\"caption\":\"STA Research\"},\"description\":\"STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/sta-research\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"American Analyst Ratings Updates: November 13th, 2026 | Stock Target Advisor","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-13th-2026\/","og_locale":"en_US","og_type":"article","og_title":"American Analyst Ratings Updates: November 13th, 2026","og_description":"Analyst Ratings Updates (USA) Applied Aerospace &amp; Defense (AADX) \u2014 Guggenheim lowered its price target from $30.00 to $15.00 and maintained a Buy rating.&hellip;","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-13th-2026\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2026-11-17T19:38:49+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2023\/02\/Desktop-1-6-1.png","type":"image\/png"}],"author":"STA Research","twitter_card":"summary_large_image","twitter_creator":"@AdvisorTarget","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"STA Research","Est. reading time":"33 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-13th-2026\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-13th-2026\/"},"author":{"name":"STA Research","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae"},"headline":"American Analyst Ratings Updates: November 13th, 2026","datePublished":"2026-11-17T19:38:49+00:00","dateModified":"2026-11-17T19:38:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-13th-2026\/"},"wordCount":6874,"commentCount":0,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News &amp; Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-13th-2026\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-13th-2026\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-13th-2026\/","name":"American Analyst Ratings Updates: November 13th, 2026 | Stock Target Advisor","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2026-11-17T19:38:49+00:00","dateModified":"2026-11-17T19:38:49+00:00","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-13th-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-13th-2026\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/american-analyst-ratings-updates-november-13th-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"American Analyst Ratings Updates: November 13th, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae","name":"STA Research","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g","caption":"STA Research"},"description":"STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.","url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/sta-research\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/77144","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=77144"}],"version-history":[{"count":2,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/77144\/revisions"}],"predecessor-version":[{"id":77147,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/77144\/revisions\/77147"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/28535"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=77144"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=77144"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=77144"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}